FDA Exclusivity Protections Blocking ‘Me Too’ Product Challenged In Lawsuit
This article was originally published in The Pink Sheet Daily
Executive Summary
Veloxis sues FDA after agency declines to approve to its extended-release immunosuppressant, Envarsus XR, until exclusivity for Astellas’ Astagraf XL expires in 2016.